Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
Status:
Not yet recruiting
Trial end date:
2025-11-12
Target enrollment:
Participant gender:
Summary
This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of
CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations